Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 75.01% is 49% below its 5-year average of 148.52%, around the middle of its 5-year range (-803.00%–689.46%).
As of the fiscal period ended Tuesday, September 30, 2025. 55.44% below its 12-month average of 168.34%.
Annual fiscal-year return on equity; no daily interpolation.
RETURN ON EQUITY (ROE)
75.01%
RETURN ON EQUITY (ROE) AVG TTM
168.34%
RETURN ON EQUITY (ROE) AVG 3Y
-32.99%
RETURN ON EQUITY (ROE) AVG 5Y
148.52%
RETURN ON EQUITY (ROE) AVG 10Y
94.79%
RETURN ON EQUITY (ROE) AVG 15Y
49.71%
RETURN ON EQUITY (ROE) AVG 20Y
26.53%
CURRENT VS TTM AVG
-55.44%
CURRENT VS 3Y AVG
+327.37%
CURRENT VS 5Y AVG
-49.50%
CURRENT VS 10Y AVG
-20.86%
CURRENT VS 15Y AVG
+50.90%
CURRENT VS 20Y AVG
+182.69%
SECTOR MEDIAN · HEALTHCARE
10.89%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
+588.80%
vs the sector median at left
Cencora, Inc.
Market Cap
$62.18B
Return on Equity (ROE)
75.01%
TTM Avg
168.34%
3Y Avg
-32.99%
5Y Avg
148.52%
Market Cap
$60.26B
Return on Equity (ROE)
4.72%
TTM Avg
6.60%
3Y Avg
6.50%
5Y Avg
6.42%
Market Cap
$68.46B
Return on Equity (ROE)
13.74%
TTM Avg
10.21%
3Y Avg
8.16%
5Y Avg
6.40%
Market Cap
$54.46B
Return on Equity (ROE)
-56.13%
TTM Avg
-41.33%
3Y Avg
9.62%
5Y Avg
-22.30%
Market Cap
$71.62B
Return on Equity (ROE)
14.08%
TTM Avg
14.72%
3Y Avg
15.95%
5Y Avg
23.11%
Market Cap
$48.18B
Return on Equity (ROE)
10.58%
TTM Avg
26.07%
3Y Avg
24.86%
5Y Avg
23.86%
Market Cap
$46.67B
Return on Equity (ROE)
6.08%
TTM Avg
7.05%
3Y Avg
11.93%
5Y Avg
15.09%
Market Cap
$44.93B
Return on Equity (ROE)
70.38%
TTM Avg
60.82%
3Y Avg
72.53%
5Y Avg
81.69%
Market Cap
$79.64B
Return on Equity (ROE)
14.90%
TTM Avg
11.32%
3Y Avg
12.19%
5Y Avg
12.83%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cencora, Inc. (COR) | $62.18B | 75.01% | 168.34% | -32.99% | 148.52% |
| Becton, Dickinson and Company (BDX)vs › | $60.26B | 4.72% | 6.60% | 6.50% | 6.42% |
| Boston Scientific Corporation (BSX)vs › | $68.46B | 13.74% | 10.21% | 8.16% | 6.40% |
| Cardinal Health, Inc. (CAH)vs › | $54.46B | -56.13% | -41.33% | 9.62% | -22.30% |
| Regeneron Pharmaceuticals, Inc. (REGN)vs › | $71.62B | 14.08% | 14.72% | 15.95% | 23.11% |
| Edwards Lifesciences Corporation (EW)vs › | $48.18B | 10.58% | 26.07% | 24.86% | 23.86% |
| Humana Inc. (HUM)vs › | $46.67B | 6.08% | 7.05% | 11.93% | 15.09% |
| IDEXX Laboratories, Inc. (IDXX)vs › | $44.93B | 70.38% | 60.82% | 72.53% | 81.69% |
| Cigna Corporation (CI)vs › | $79.64B | 14.90% | 11.32% | 12.19% | 12.83% |
| Elevance Health Inc. (ELV)vs › | $83.65B | 11.06% | 13.69% | 14.71% | 14.93% |
ROE
75.0%
ROA
3.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-09-30 | 103.06% |
| 2024-09-30 | 233.63% |
| 2023-09-30 | 334.35% |
| 2022-09-30 | -803.00% |
| 2021-09-30 | 689.46% |
| 2020-09-30 | 333.64% |
| 2019-09-30 | 29.71% |
| 2018-09-30 | 56.55% |
| 2017-09-30 | 20.08% |
| 2016-09-30 | 67.06% |
| 2015-09-30 | -21.88% |
| 2014-09-30 | 14.13% |
| 2013-09-30 | 18.70% |
| 2012-09-30 | 29.27% |
| 2011-09-30 | 24.65% |
| 2010-09-30 | 21.55% |
| 2009-09-30 | 18.53% |
| 2008-09-30 | 9.25% |
| 2007-09-30 | 15.14% |
| 2006-09-30 | 11.29% |
| 2005-09-30 | 7.46% |
| 2004-09-30 | 10.79% |
| 2003-09-30 | 11.02% |
| 2002-09-30 | 10.40% |
| 2001-09-30 | 4.41% |
| 2000-09-30 | 35.07% |
| 1999-09-30 | 40.59% |
| 1998-09-30 | 67.07% |
| 1997-09-30 | 317.48% |
| 1996-09-30 | -96.47% |
